Brown Advisory Inc. Has $667.33 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

Brown Advisory Inc. reduced its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 5.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,095,796 shares of the company's stock after selling 235,296 shares during the period. Zoetis makes up about 0.8% of Brown Advisory Inc.'s investment portfolio, making the stock its 28th largest position. Brown Advisory Inc. owned approximately 0.91% of Zoetis worth $667,328,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Callahan Advisors LLC lifted its holdings in shares of Zoetis by 90.4% during the fourth quarter. Callahan Advisors LLC now owns 13,105 shares of the company's stock valued at $2,135,000 after purchasing an additional 6,221 shares during the last quarter. CIBC Asset Management Inc lifted its stake in Zoetis by 24.1% during the fourth quarter. CIBC Asset Management Inc now owns 237,369 shares of the company's stock valued at $38,617,000 after buying an additional 46,050 shares in the last quarter. Pensionfund Sabic lifted its stake in Zoetis by 55.6% during the fourth quarter. Pensionfund Sabic now owns 11,200 shares of the company's stock valued at $1,825,000 after buying an additional 4,000 shares in the last quarter. Schroder Investment Management Group boosted its holdings in shares of Zoetis by 2.6% in the fourth quarter. Schroder Investment Management Group now owns 245,726 shares of the company's stock worth $40,036,000 after buying an additional 6,169 shares during the period. Finally, PFW Advisors LLC purchased a new position in shares of Zoetis in the fourth quarter worth approximately $1,764,000. 92.80% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the sale, the executive vice president now directly owns 15,781 shares in the company, valued at approximately $2,682,770. The trade was a 2.02 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the company's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the sale, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,862 shares of company stock valued at $312,254 in the last quarter. Corporate insiders own 0.16% of the company's stock.

Wall Street Analysts Forecast Growth

ZTS has been the subject of a number of recent analyst reports. StockNews.com raised shares of Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. Piper Sandler raised their target price on Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research report on Thursday, February 27th. Morgan Stanley dropped their price target on Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. Stifel Nicolaus lowered their target price on Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. Finally, Barclays increased their price target on shares of Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research report on Friday, February 14th. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Zoetis presently has a consensus rating of "Buy" and an average price target of $214.40.

Zoetis Stock Performance

Shares of NYSE:ZTS traded down $8.24 during trading on Tuesday, reaching $149.82. The stock had a trading volume of 4,122,056 shares, compared to its average volume of 2,474,560. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The stock has a fifty day simple moving average of $157.87 and a two-hundred day simple moving average of $166.69. The firm has a market capitalization of $66.85 billion, a price-to-earnings ratio of 27.39, a P/E/G ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08. The company had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The company's revenue for the quarter was up 1.4% on a year-over-year basis. During the same period in the previous year, the business posted $1.38 EPS. As a group, analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.33%. The ex-dividend date is Monday, April 21st. Zoetis's dividend payout ratio (DPR) is presently 36.56%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.